Home▸Hidradenitis Suppurativa Scoring & Treatment▸Adalimumab Biologic Therapy for HS Simulator

🔥 Adalimumab Biologic Therapy for HS Simulator

This simulator models the use of adalimumab in treating moderate to severe hidradenitis suppurativa, providing insights into the efficacy and potential side effects of this biologic therapy for managing the condition.

Hidradenitis Suppurativa Scoring & Treatment2DModerate60 FPS

TNF-alpha and Follicular Inflammation in Hidradenitis Suppurativa

Chronic TNF-alpha signaling drives painful nodules and abscesses in HS.

~1%: Prevalence (placeholder population estimate)
Post-puberty: Onset (placeholder typical age)
TNF-α: Key cytokine (placeholder driver)
Axilla/groin: Sites (placeholder distribution)

Inflammatory cascade in HS lesions

Placeholder: follicular occlusion triggers TNF-alpha-driven immune activation.

Loading Dose Induction with Adalimumab

An initial high-dose regimen rapidly reduces circulating free TNF-alpha.

160mg: Loading dose (placeholder week 0)
80mg: Second dose (placeholder week 2)
Subcutaneous: Route (placeholder injection)
~2-4wk: Onset of effect (placeholder timeline)

Induction dosing rationale

Placeholder: front-loaded dosing achieves therapeutic drug levels quickly.

How Adalimumab Neutralizes TNF-alpha

The monoclonal antibody binds soluble and membrane TNF-alpha directly.

TNF-α: Target (placeholder cytokine)
IgG1 mAb: Antibody type (placeholder isotype)
High affinity: Binding (placeholder Kd)
Blocks signaling: Effect (placeholder outcome)

Antibody-cytokine neutralization

Placeholder: bound TNF-alpha cannot engage its receptors on target cells.

Long-Term Maintenance Dosing Schedule

Weekly subcutaneous injections sustain blockade and prevent flares.

40mg: Maintenance dose (placeholder weekly)
Weekly: Frequency (placeholder interval)
Long-term: Duration (placeholder ongoing)
Periodic labs: Monitoring (placeholder safety)

Sustaining therapeutic levels

Placeholder: consistent dosing avoids trough-related symptom breakthrough.

HiSCR — Hidradenitis Suppurativa Clinical Response

HiSCR tracks abscess and nodule reduction to gauge treatment success.

≥50% AN: HiSCR definition (placeholder reduction)
Week 12: Assessment week (placeholder checkpoint)
Reassess: Non-response action (placeholder pathway)
Continue: Responder action (placeholder pathway)

Interpreting HiSCR outcomes

Placeholder: response status guides continuation or therapy switch decisions.

Placeholder: sustained HiSCR response supports long-term continuation.

⚙ Under the hood

CanvasBiomedicine

2D · HTML5 Canvas 2D · 60 FPS target · runs fully client-side, no install